[Clinical usefulness of serum IFN-gamma level in patients with chronic obstructive pulmonary disease]. 1999

B Chen, and Y Feng, and S Li, and Y Cai
Department of Respiratory Disease, First Affiliated Hospital, WCUMS, Chengdu 610041.

The objective of this study was to gain a clear idea of rule of change in serum IFN-gamma level in patients with chronic obstructive pulmonary disease and to evaluate the clinical usefulness of IFN-gamma as a marker of immune condition. The serum IFN-gamma levels of 15 patients with chronic bronchitis, 15 patients with cor pulmonale, 15 patients with acute bronchitis, and 15 normal subjects were measured by radio-immuno-assay. Differences between the four groups were tested, and in the chronic bronchitis group, the serum IFN-gamma levels, before and after treatment were compared. The results showed that compared with the normal group (0.8 +/- 0.17 IU/ml), the serum level changed little in the cor pulmonale group (0.93 +/- 0.25 IU/ml); it was not higher in the chronic bronchitis group (1.23 +/- 0.39 IU/ml, P > 0.05), but it went up significantly after treatment for 7 days (1.84 +/- 0.51 IU/ml, P < 0.05). The highest level of IFN-gamma was noted in the acute bronchitis group (2.24 +/- 0.71 IU/ml, P < 0.01). There was a significant difference compared with other groups (P < 0.01). These results suggest that relative deficiency of serum IFN-gamma may be a factor inducing repeated respiratory infection, and the serum level of IFN-gamma can be used as an index to assess the immune condition of patients with chronic obstructive pulmonary disease.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D029424 Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA. Airflow Obstruction, Chronic,COAD,COPD,Chronic Airflow Obstruction,Chronic Obstructive Airway Disease,Chronic Obstructive Lung Disease,Chronic Obstructive Pulmonary Disease,Chronic Obstructive Pulmonary Diseases,Airflow Obstructions, Chronic,Chronic Airflow Obstructions

Related Publications

B Chen, and Y Feng, and S Li, and Y Cai
February 2013, Multidisciplinary respiratory medicine,
B Chen, and Y Feng, and S Li, and Y Cai
January 2014, Pneumologia (Bucharest, Romania),
B Chen, and Y Feng, and S Li, and Y Cai
August 2020, Journal of alternative and complementary medicine (New York, N.Y.),
B Chen, and Y Feng, and S Li, and Y Cai
January 1992, Journal of biological regulators and homeostatic agents,
B Chen, and Y Feng, and S Li, and Y Cai
November 1996, Thrombosis research,
B Chen, and Y Feng, and S Li, and Y Cai
January 2023, International journal of chronic obstructive pulmonary disease,
B Chen, and Y Feng, and S Li, and Y Cai
January 2018, International journal of chronic obstructive pulmonary disease,
Copied contents to your clipboard!